The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 June 2026•

1 min read

Citigroup Raises Zymeworks Price Target to $37 After Theravance Acquisition

Key Facts

1Citigroup reiterated its 'Buy' rating on Zymeworks and raised the price target to $37 from $35.

2Zymeworks is set to acquire Theravance Biopharma in an all-cash transaction valued at approximately $929 million.

Amid ongoing M&A activity in the biotech sector, Citigroup reiterated its 'Buy' rating on Zymeworks (ZYME) and raised its price target to $37 from $35, according to reports. The move follows Zymeworks' announcement to acquire Theravance Biopharma (TBPH) in an all-cash transaction valued at approximately $929 million. Citigroup highlighted that the acquisition adds the COPD treatment YUPELRI, which is projected to generate approximately $60 million in annualized cash flow.

Per market data, Zymeworks shares closed at $24.10 on June 29, 2026, while Theravance closed at $17.06 the same day. The new price target implies roughly 53% upside from Zymeworks' last close, reflecting the positive outlook on the deal. The transaction is supported by a unique financing structure including a $350 million non-recourse note and a potential future $100 million milestone payment, which eases the financial burden on Zymeworks.

Investors are now focused on the closing of the deal and expected regulatory approvals. The price target of $37 suggests significant upside from the prior close of $24.10. The coming period may also see attention on cash flow developments from YUPELRI, a key value driver post-merger.